Huntington's disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Molecular Pathology

• Publication date

  2001-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/mp.54.6.409PMID 11724916PMCID PMC1187131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation of a 40-kDa Huntingtin-associated Protein*

  2001cited by this paper
• Molecular physiology of kainate receptors.

  2001cited by this paper
• NMDA receptor subunits: diversity, development and disease.

  2001cited by this paper
• Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine

  2001cited by this paper
• Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95*

  2001cited by this paper
• Kainate Receptor Activation Induces Mixed Lineage Kinase-mediated Cellular Signaling Cascades via Post-synaptic Density Protein 95*

  2001cited by this paper
• Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.

  2001cited by this paper
• The molecular biology of Huntington's disease

  2001cited by this paper
• Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

  2001cited by this paper
• Loss of normal huntingtin function: new developments in Huntington's disease research.

  2001cited by this paper
• Activated JNK Phosphorylates the C-terminal Domain of MLK2 That Is Required for MLK2-induced Apoptosis*

  2001cited by this paper
• Tissue-Specific Proteolysis of Huntingtin (htt) in Human Brain: Evidence of Enhanced Levels of N- and C-Terminal htt Fragments in Huntington's Disease Striatum

  2001cited by this paper
• Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production.

  2001cited by this paper
• Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity

  2001cited by this paper
• Brain-derived neurotrophic factor in Huntington disease.

  2000cited by this paper
• Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles.

  2000cited by this paper
• Huntingtin Interacting Protein 1 Induces Apoptosis via a Novel Caspase-dependent Death Effector Domain*

  2000cited by this paper
• Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease.

  2000cited by this paper
• Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy

  2000cited by this paper
• Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.

  2000cited by this paper
• NMDA receptors in the basal ganglia

  2000cited by this paper
• HIP12 is a non-proapoptotic member of a gene family including HIP1, an interacting protein with huntingtin

  2000cited by this paper
• Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.

  2000cited by this paper
• Isoprostanes, Novel Markers of Oxidative Injury, Help Understanding the Pathogenesis of Neurodegenerative Diseases

  2000cited by this paper
• Proton magnetic resonance spectroscopy of cerebrospinal fluid in neurodegenerative disease: Indication of glial energy impairment in Huntington chorea, but not Parkinson disease

  2000cited by this paper
• Huntington disease: new insights on the role of huntingtin cleavage.

  2000cited by this paper
• The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

  2000cited by this paper
• Gender of the embryo contributes to CAG instability in transgenic mice containing a Huntington's disease gene.

  2000cited by this paper
• Transcriptional dysregulation in Huntington's disease.

  2000cited by this paper
• Changes in mRNA for post-synaptic density-95 (PSD-95) and carboxy-terminal PDZ ligand of neuronal nitric oxide synthase following facial nerve transection.

  2000cited by this paper
• Huntington's disease: the challenge for cell biologists.

  2000cited by this paper
• Activation of MLK2-mediated Signaling Cascades by Polyglutamine-expanded Huntingtin*

  2000cited by this paper
• A one-hit model of cell death in inherited neuronal degenerations

  2000cited by this paper
• The Status of SCA1, MJD/SCA3, FRDA, DRPLA and MD Triplet Containing Genes in Patients with Huntington Disease and Healthy Controls

  2000cited by this paper
• No Evidence for Increased Oxidative Damage to Lipids, Proteins, or DNA in Huntington's Disease

  2000cited by this paper
• Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

  2000cited by this paper
• The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.

  2000cited by this paper
• Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice.

  2000cited by this paper
• Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage.

  2000cited by this paper
• Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?

  2000cited by this paper
• Molecular basis of the neurodegenerative disorders.

  1999cited by this paper
• An Actin-Binding Protein of the Sla2/Huntingtin Interacting Protein 1 Family Is a Novel Component of Clathrin-Coated Pits and Vesicles

  1999cited by this paper
• Kainate receptors: subunits, synaptic localization and function.

  1999cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• Recent advances on the pathogenesis of Huntington's disease.

  1999cited by this paper
• Forskolin and dopamine D1 receptor activation increase huntingtin's association with endosomes in immortalized neuronal cells of striatal origin.

  1999cited by this paper
• Recent advances in understanding the pathogenesis of Huntington's disease.

  1999cited by this paper
• Distinct Influx Pathways, Not Calcium Load, Determine Neuronal Vulnerability to Calcium Neurotoxicity

  1998cited by this paper
• Movement Disorders

  1998cited by this paper
• Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

  1998cited by this paper
• Expression of Polyglutamine-expanded Huntingtin Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line*

  1998cited by this paper
• Cloning, expression analysis, and chromosomal localization of HIP1R, an isolog of huntingtin interacting protein (HIP1)

  1998cited by this paper
• Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene

  1997cited by this paper
• Glutamate, But Not Dopamine, Stimulates Stress-Activated Protein Kinase and AP-1-Mediated Transcription in Striatal Neurons

  1997cited by this paper
• Neurobiology of Huntington's disease.

  1996cited by this paper
• HEAT repeats in the Huntington's disease protein

  1995cited by this paper
• Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons.

  1995cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• A polymorphic DNA marker genetically linked to Huntington's disease

  1983cited by this paper

• The Potential of Nanopore Technologies in Peptide and Protein Sensing for Biomarker Detection

  2025cites this paper
• Genetically Modified Primate Models for Brain Disorder Research

  2025cites this paper
• Impacts of H2O2, SARM1 inhibition, and high NAm concentrations on Huntington's disease laser‐induced degeneration

  2024cites this paper
• Exploring therapeutic potential: Targeting TRPM7 in neurodegenerative diseases.

  2024cites this paper
• Selenium Nanoparticles as Neuroprotective Agents: Insights into Molecular Mechanisms for Parkinson’s Disease Treatment

  2024cites this paper
• EVALUATION OF ANTAGONIST ACTIVITY OF IFENPRODIL AND THEIR ANALOGOUS AGAINST GLUN1/GLUN2B USING IN SILICO MOLECULAR DOCKING AND ABSORPTION-DISTRIBUTIONMETABOLISM- EXCRETION TOXICITY

  2022cites this paper
• GluN2A‐Selective NMDA Receptor Antagonists: Mimicking the U‐Shaped Bioactive Conformation of TCN‐201 by a [2.2]Paracyclophane System

  2022cites this paper
• Negative allosteric modulators of the GluN2B NMDA receptor with phenylethylamine structure embedded in ring-expanded and ring-contracted scaffolds.

  2020cites this paper
• Combination of stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice

  2019cites this paper
• Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists.

  2019cites this paper
• Impact of hydroxy moieties at the benzo[7]annulene ring system of GluN2B ligands: Design, synthesis and biological evaluation.

  2019cites this paper
• The Puzzling Role of Neuron-Specific PMCA Isoforms in the Aging Process

  2019cites this paper
• Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold.

  2019cites this paper
• Fluorinated GluN2B Receptor Antagonists with a 3‐Benzazepine Scaffold Designed for PET Studies

  2018cites this paper
• Rotating and Neurochemical Activity of Rats Lesioned with Quinolinic Acid and Transplanted with Bone Marrow Mononuclear Cells

  2018cites this paper
• Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease.

  2018cites this paper
• Progress in developing transgenic monkey model for Huntington’s disease

  2018cites this paper
• Hydroxymethyl bioisosteres of phenolic GluN2B-selective NMDA receptor antagonists: Design, synthesis and pharmacological evaluation.

  2018cites this paper
• Comparative Pharmacological Study of Common NMDA Receptor Open Channel Blockers Regarding Their Affinity and Functional Activity toward GluN2A and GluN2B NMDA Receptors

  2018cites this paper
• Physiology, NMDA Receptor

  2018cites this paper
• Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.

  2018cites this paper
• Cell-based technologies for Huntington’s disease

  2016cites this paper
• The Role of Cathepsin D in the Pathogenesis of Human Neurodegenerative Disorders

  2016cites this paper
• Neurodegenerative diseases: From available treatments to prospective herbal therapy.

  2016cites this paper
• Protein aggregation and neurodegenerative diseases: From theory to therapy.

  2016cites this paper
• Trastornos del movimiento (III): síndromes coreicos y distonía

  2015cites this paper
• Flavonoid-based therapies in the early management of neurodegenerative diseases.

  2015cites this paper
• PROBLEMS EDITING THE MONKEY GENOME

  2014cites this paper
• Induction of apoptosis by antimycin A in differentiated PC12 cell line

  2014cites this paper
• A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: looking for biomarkers

  2013cites this paper
• Sirtuin Deacetylases as Therapeutic Targets in the Nervous System

  2013cites this paper
• NMDA Receptor Activity in Neuropsychiatric Disorders

  2013cites this paper
• Pluripotent hybrid stem cells from transgenic Huntington's disease monkey.

  2013cites this paper
• Pluripotent stem cells models for Huntington's disease: prospects and challenges.

  2012cites this paper
• [The role of proteins in neurodegenerative disease].

  2012cites this paper
• Organoselenium Bis Selenide Attenuates 3-Nitropropionic Acid-Induced Neurotoxicity in Rats

  2012cites this paper
• Huntington’s Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy

  2011cites this paper
• Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.

  2011cites this paper
• Ing and neurodegenerat Ion on dendr It Ic sp Ine morphology

  2011cites this paper
• Oxidative Stress in Neurodegeneration

  2011cites this paper
• Synaptic Dysfunction in Huntington’s Disease

  2011cites this paper
• Influence of aging and neurodegeneration on dendritic spine morphology

  2011cites this paper
• Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats.

  2010cites this paper
• Reprogramming Huntington Monkey Skin Cells into Pluripotent Stem Cells

  2010cites this paper
• Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors

  2010cites this paper
• Huntingtin associated protein 1 and its functions

  2009cites this paper
• The CREB/CRE transcriptional pathway: protection against oxidative stress‐mediated neuronal cell death

  2009cites this paper
• BDNF and extracellular matrix regulate differentiation of mice neurosphere‐derived cells into a GABAergic neuronal phenotype

  2009cites this paper
• Transcriptional Regulation of NMDA Receptor Expression

  2009cites this paper
• Towards a transgenic model of Huntington’s disease in a non-human primate

  2008cites this paper
• Protein folding diseases and neurodegeneration: lessons learned from yeast.

  2008cites this paper
• Establishment of an immortalized GABAergic neuronal progenitor cell line from embryonic ventral mesencephalon in the rat.

  2008cites this paper
• A Review of Glutamate Receptors II: Pathophysiology and Pathology

  2008cites this paper
• Organische Störungen, Demenzen

  2008cites this paper
• Transgenic Animal Models of Neurodegenerative Diseases

  2008cites this paper
• Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants

  2008cites this paper
• The cellular prion protein

  2007cites this paper
• N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.

  2007cites this paper
• The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system.

  2007cites this paper
• Neuroprotective effects of steroid analogues on P19-N neurons.

  2007cites this paper
• Trastornos del movimiento (III): s?ndromes coreicos y diston?a

  2007cites this paper
• Protective up‐regulation of CK2 by mutant huntingtin in cells co‐expressing NMDA receptors

  2007cites this paper
• FUNCTIONS OF THE UNIQUE N-TERMINUS OF A GCN5 HISTONE ACETYLASE IN TOXOPLASMA GONDII

  2007cites this paper
• Mitochondria and Neurodegeneration

  2007cites this paper
• Huntington's Disease with Onset in Childhood - Clinical Presentation as Drug-Resistent Epilepsy

  2006cites this paper
• Responses of the Adult SVZ to Neuronal Death and Injury

  2006cites this paper
• Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat.

  2006cites this paper
• gene and early onset dementia Octapeptide repeat insertions in the prion protein

  2006cites this paper
• Selective neuronal degeneration in Huntington's disease.

  2006cites this paper
• EL RECEPTOR IONOTRÓPICO DE GLUTAMATO ACTIVADO POR N-METIL-D-ASPARTATO, MOLÉCULA CLAVE DE LA CONCIENCIA

  2006cites this paper
• Genes and the Environment in Neurodegeneration

  2006cites this paper
• CHAPTER 100 – Vitamin D, A Neuroactive Hormone: From Brain Development to Pathological Disorders

  2005cites this paper
• Firing up the nature/nurture controversy: bioethics and genetic determinism

  2005cites this paper
• Firing up the nature/nurture controversy: bioethics and genetic determinism

  2005cites this paper
• Proteinaceous intracellular inclusions in neurodegenerative disorders.

  2005cites this paper
• Uncommon neurodegenerative causes of dementia

  2005cites this paper
• Substrates for Transglutaminase-Catalyzed Cross-Linking: Relevance to Pathogenesis of Huntington’s Disease and Chorea-Acanthocytosis

  2004cites this paper
• Neuronal Apoptosis in Neurodegenerative Diseases: From Basic Research to Clinical Application

  2004cites this paper
• Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes.

  2004cites this paper
• Protective effect of melatonin on 3‐nitropropionic acid‐induced oxidative stress in synaptosomes in an animal model of Huntington's disease

  2004cites this paper
• Dendritic spine pathology and deficits in experience‐dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice

  2004cites this paper
• Cell-Death Mechanisms in Neurodegenerative Diseases

  2003cites this paper
• Purification and inactivation of 3-hydroxyanthranilic acid 3,4-dioxygenase from beef liver.

  2003cites this paper
• Cells exposed to a huntingtin fragment containing an expanded polyglutamine tract show no sign of ion channel formation: Results arguing against the ion channel hypothesis

  2003cites this paper
• NERVE GROWTH FACTOR AND FIBROBLAST GROWTH FACTOR PREVENTS ACUTE QA-EXCITOTOXICITY IN RAT BASAL FOREBRAIN

  2003cites this paper
• Genetic association of Huntington's disease and restless legs syndrome? A family report

  2003cites this paper
• Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain.

  2002cites this paper
• Genetics of the dementias

  2002cites this paper
• A simple sensitive program for detecting internal repeats in sets of multiply aligned homologous proteins.

  2002cites this paper